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1. Introduction
Glimepiride is a new third generation 
sulphonylurea oral hypoglycaemic agent. It has 
been proposed for the treatment of type-2 
diabetes, whenever blood glucose levels cannot 
be adequately controlled by diet, physical 
exercise and weight reduction alone. 
Glimepiride enhances the normal action of 
insulin on peripheral glucose uptake (insulin-
sensitizing effect). It also enhances peripheral 
glucose uptake and inhibits glucose output 
(insulin-mimetic effects). It directly increases 
the number of glucose transporters in the plasma 
membranes of muscle and fat cell. In 
comparison to other sulphonylurea antidiabetic 
drugs, glimepiride expresses an insulin-sparing 
effect and minimal interaction with the 
cardiovascular system (1, 2).  
However, current glimepiride formulations 
have some adverse effects and bioavailability 
problems. Its bioavailability problems are 
encountered because of its poor pH dependent 
solubility. This poor aqueous solubility 
(0.001908 mg/ml) and hence slow dissolution 
may lead to irreproducible clinical response; 
high inter individual variations and inappropriate 
maintenance of blood levels of the drug and 
glucose. In some cases, therapeutic failure 
occurs due to subtherapeutic plasma drug levels 
(3-5). The most frequently reported adverse 
events are hypoglycemia, dizziness and 
headache. Moreover, oral therapy may cause 
gastric disturbances, heartburn, nausea and 
diarrhea which greatly affect patient compliance 
(6).  
Poor compliance with medication is a major 
barrier to successful patient management in type 
2 diabetes. Establishing and maintaining 
effective glycemic control in patients reduce the 
risk of long-term microvascular and 
macrovascular complications.  
New anti-diabetic regimens are urgently 
required. One possibility involves drug delivery 
across the skin. Transdermal delivery could be 
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an alternative route to overcome many of the 
problems associated with the oral therapy. 
Recently, the transdermal route has vied with 
oral treatment as the most successful innovative 
research area in drug delivery (7). 
Advantages of the transdermal delivery over 
other forms of administration include improved 
patient compliance due to less frequent dosing, 
avoidance of the hostile gastrointestinal 
environment and its impact not only on the drug 
absorption but also on its stability, avoidance of 
first pass effect, maintenance of uniform 
systemic drug within the therapeutic level for 
prolonged time, reduction of inter- and intra- 
patient variability, termination of the drug input 
simply by the removal of the patch (8). 
Recently, different oral antidiabetic 
sulphonylurea drugs have been subjected to 
extensive investigations for their appropriateness 
to be delivered via transdermal route e.g., 
glibenclamide, chloropropamide (9-11), 
gliquidone (12) and glipizide (13, 14). The 
results were very promising. However, the 
literature revealed that the studies on 
transdermal delivery of glimepiride were very 
rare. Glimepiride was the subject of a single 
study aimed at development of a transdermal 
system (15). The study investigated the 
pharmacokinetics and relative bioavailability of 
glimepiride gelmatrix patch in rats; the results 
revealed that the patch exhibited good 
controlled-release and bioavailability properties. 
The importance of glimepiride, in spite of its 
oral administration problems in the aspect of its 
unique benefits compared to other members of 
the oral antidiabetic sulphonylurea group, 
motivated our study to design an acceptable, 
simple, safe, economic and prolonged release 
transdermal formula for glimepiride.  
In the current research, the use of chitosan 
was inspected for potentiality to develop a 
transdermal delivery system for glimepiride. 
Chitosan molecule is a copolymer of N-acetyl-
D-glucosamine and D-glucosamine, which are 
constituents of normal mammalian tissue, thus 
provides biocompatibility. In recent years 
chitosan has gained increasing interest in 
pharmaceutical field due to its favorable 
biological properties such as biodegradability 
and lack of toxicity, together with its wide 
availability in nature and low cost (16, 17). From 
the biopharmaceutical view point, chitosan has 
an original characteristic of mucoadhesion
18
. It 
has film forming and gelation abilities, along 
with its absorption enhancing properties and 
versatility in development of several drug 
delivery systems (19). It enhances the 
paracellular drug transport via transient opening 
of tight junction between epithelial cells (20, 
21). Furthermore, it has demonstrated its 
effectiveness in improving dissolution properties 
and bioavailability of poorly-soluble drugs (22).  
Vehicles designed to enhance drug delivery 
through the skin must incorporate specific 
elements that improve the ability of the delivery 
system to overcome the barrier posed by the 
stratum corneum (23). Thus, we investigated 
inclusion complexation of glimepiride with β–
cylodextrin in view of its ability to improve the 
solubility of the drug. It was stated that the 
solubility of glimepiride was increased markedly 
by complexation with β-CyD. The solubilizing 
power, calculated as mole glimepiride 
solubilized per one mole of cyclodextrin, was 
0.003 (24). The solubility study had revealed the 
existence of a phase solubilizing diagram of the 
Ap type indicating the formation of high order 
complex between the drug and the cyclodextrin 
(24). Cyclodextrins are able to form both 
inclusion and non-inclusion complexes. These 
complexes are also able to solubilize lipophilic 
water insoluble drugs through inclusion 
complexation in addition to non-inclusion 
complexation or micelle-like structure 
formation.  
Also, CyDs are able to increase dermal and 
transdermal drug delivery without affecting the 
barrier function of the skin (25-28). In addition, 
various conventional penetration enhancers 
belonging to different chemical groups were 
monitored to assess their penetration enhancing 
effect towards the drug. The developed formulae 
of the drug were evaluated for permeation, as 
well as for their impact on the biological 
performance of the drug. 
2. Materials and Methods 
2.1. Materials 
Glimepiride was kindly provided by Delta 
Pharma. Co. (Mumbai, India). Chitosan (MW 
150,000, deacetylation degree 75–85%), β-
cyclodextrin, cineole, menthol, limonene and 
streptozotocin were purchased from Sigma 
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Chemical Company (St. Louis, USA). Oleic acid 
was purchased from Fluka (Germany). Sodium 
dihydrogen phosphate was supplied from S. D. 
fine-chem. Ltd. (Mumbai, India) and disodium 
hydrogen phosphate was purchased from BDH 
Laboratory Supplies (Poole England). Lactic 
acid, acetic acid and ethanol were supplied from 
Adwic, Banglore. All other ingredients are of 
analytical grade. 
2.2. Methods 
2.2.1. Elucidation of the Stoichiometric Ratio 
and Preparation of Glimepiride-β –
Cyclodextrin Complex 
The continuous variation method (29)
 
was 
utilized to determine the stoichiometric ratio of 
glimepiride-β-CyD complex by 
spectrophotometric measurements. The 
absorbance values of fixed total concentration 
(0.072 mmol/l) of glimepiride and β-CyD were 
measured at 226 nm. If it was found that the 
absorbance values of these solutions were 
different from the sum of the corresponding 
values of their components. Then, the observed 
absorbance difference was plotted against mole 
fraction.  
Inclusion complex of glimepiride in β-CyD 
was prepared by the kneading method (30), 
whereby glimepiride was added to the 
cyclodextrin in a molar ratio equivalent to its 
corresponding stoichiometric ratio in the 
complex, kneaded thoroughly with least amount 
of water to obtain a paste which was then dried 
under vacuum at room temperature in presence 
of phosphorus pentoxide as a drying agent. 
2.2.2. Preparation of Chitosan Films 
Chitosan (1.5% w/v) was dissolved in water 
containing 2 % w/v of a 1:1 mixture of lactic 
acid and acetic acid solution and stirred 
overnight using a magnetic stirrer. The resulting 
solution was filtered through a sintered glass 
filter to remove the extraneous matter. The 
resulting solution was medicated with the drug 
or its equivalent amount of the glimepiride 
complex followed by sonication for 2 hours. 
Two concentrations of glimepiride were used in 
preparing the films. The first was 0.30 % w/w 
and the second was 0.125% w/w. The first 
concentration, suitable for human, was used for 
preparing films having a dose of (6 mg/3cm
2
) 
which were used for in vitro evaluation. The 
second concentration was used in preparing 
films comprising a dose (2.5 mg/3cm
2
), suitable 
for rats, these films were used for in-vivo 
assessment. In case of investigating penetration 
enhancers, they were added at this step in the 
corresponding concentrations followed by 
sonication for 1 hour. The mixtures were then 
casted on teflon plates and dried in an incubator 
at 25°C for 24 hours. The spreading volume was 
0.9 ml / cm
-2
. The mixture was spread uniformly. 
After drying, the films were carefully peeled off. 
The films, with uniform thickness = 200 ± 25 
µm, were stored in tight glass containers 
maintained at room temperature until further 
investigations.  
2.2.3. Measurement of Mechanical Properties 
of Chitosan Films 
The mechanical properties (tensile strength 
and elongation at break) were measured at room 
temperature on an electric tensile testing 
machine (Zwick 1425) according to ASTM D 
412 (31). The tensile strength and elongation at 
break were calculated as follows: 
Tensile strength (N/mm
2
) = Breaking force (N) 
/Cross sectional area (mm)
 2
 
Elongation at break % = (Increase in length at 
break (mm) /Original length) x100) 
2.2.4. Characterization of Glimepiride – 
Chitosan Films 
2.2.4.1. IR Studies 
The IR spectra were recorded using a 
Shimadzu 435 U-O4 IR spectrophotometer by 
KBr disc method. Prior to measurement, the 
films were cut and then ground with a small 
vibrating mill (Shimadzu vibrating mill, Japan) 
before grinding with KBr. 
2.2.4.2. X-Ray Diffraction Studies 
The X-ray diffractograms were recorded at 
room temperature using a Diano X-ray 
diffractometer equipped with Co Kα. The tube 
operated at 45 kV, 9 mA. The dried film of 
uniform thickness was carefully placed on glass 
slide and scanned in the 2 θ range of 5–80°.  
2.2.5. Release Studies 
Chitosan films, of 3.0 cm
2
 surface area, 
comprising 6 mg of glimepiride or its equivalent 
amount of glimepiride-β-CyD complex were 
applied on a glass slide and covered with 
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stainless steel mesh screen and clamped together 
(14). The assembly was placed at the bottom of 
the USP dissolution tester (Erweka Apparatebau 
GmbH, model DT-D, Germany). The release 
studies were carried out according to the paddle 
method (32). The height of the paddle from the 
surface of the assembly was adjusted to 2.5 cm. 
The vessel contained 900 ml phosphate buffer 
solution (pH=5.5), the temperature was adjusted 
at 32°C and the speed at 50 rpm. Aliquots of 5 
ml were withdrawn from the release medium at 
each time interval through sintered glass filter 
and replaced by equivalent amounts of the buffer 
solution. The amount of drug released from the 
bases was determined spectrophotometrically at 
226 nm using Shimadzu UV Spectrophotometer 
(2401/PC), Japan. Blank experiments were 
simultaneously performed. The amount of drug 
released per unit surface area was plotted against 
time and the release rate was calculated and 
statistically analyzed using the T-test for 
statistical analysis. This statistical analysis was 
computed using the SPSS® software.  
2.2.6. Permeation Studies 
Permeation studies were carried for chitosan 
films comprising glimepiride alone or as a β-
CyD complex. In addition, different penetration 
enhancers were assessed for their impact on drug 
permeation. These enhancers comprised: oleic 
acid, cineol, limonene, menthol and ethanol.  
Male Wistar rats (200 to 250 g) were 
sacrificed, the abdominal skin was excised and 
the adhering fat eliminated. The abdominal hair 
was removed carefully using electric razors. The 
whole thickness skin was equilibrated in 
phosphate buffer solution (pH = 7.4) for 1 hr 
before the beginning of each experiment. The 
skin used was of thickness 0.8 ± 0.05 mm. The 
prepared films of 3.0 cm
2
 surface area, 
comprising 6 mg of glimepiride or its equivalent 
amount of glimepiride-β-CyD complex, with or 
without conventional penetration enhancers, 
were applied firmly on the epidermis to assure 
adhesiveness. Skin was mounted on vertical 
Franz-type diffusion cell with the dermis facing 
the receptor compartment. The receptor 
compartment was filled with phosphate buffer 
solution (pH = 7.4).Then, the donor and receptor 
compartments were clamped together. The donor 
compartment was covered with parafilm. The 
jacketed cells were circulated with thermostated 
water maintained at 37°C. The temperature was 
maintained at 37 ± 0.5 °C and the receptor 
compartment, 50 ml volume capacity, was 
constantly stirred at 300 rpm. Samples of 
receptor fluid (1ml) were withdrawn 
periodically, up to 24 hours, and replenished 
with fresh buffer solution. The samples were 
assayed for the drug spectrophotometrically at 
226 nm. Blank experiments for the investigated 
films free from drug were carried concurrently. 
The amount of drug was measured against the 
blank. Steady-state flux was estimated from the 
slope of the straight-line portion of the 
cumulative amount of drug permeated per cm2of 
the patch against time profile. The data were 
analyzed statistically by the one-way ANOVA 
test followed by the least significant difference 
procedure. This statistical analysis was 
computed using the SPSS
®
 software.  
2.2.7. Assessment of Therapeutic Efficacy 
Therapeutic efficacy assessment was 
conducted on streptozotocin- induced diabetic 
rats, whereby the decrease in blood glucose level 
(BGL) was taken as a pharmacodynamic 
parameter for evaluating the bioavailability of 
the drug (33). Male Wistar rats weighing 200–
250 g were kept on standard diet and maintained 
under controlled conditions of humidity (30-
70%) and temperature (24±2°C). The animals 
were fasted overnight and then intraperitoneally 
injected with 50 mg/kg streptozotocin (34, 35) 
10–14 days prior to the study for inducing 
diabetes. Fasting blood glucose level was 
assessed using Fast Take glucometer 
SmartScan® (36). Rats having moderate 
diabetes, with fasting BGL in the range of 200-
300 mg/dl, were selected for the study. The 
animals were divided into 5 groups each 
comprising 12 rats. The first group was given the 
drug orally in a dose of 10 mg/kg body weight 
(37). Chitosan film of surface area 3.0 cm
2
 
comprising a dose of 2.5 mg glimepiride 
(formula 1) was applied tightly to ensure its 
adhesiveness on the shaved back region of the 
animals of the second group. Then, it was 
covered with a piece of aluminum foil and an 
adhesive tape. The same formula in presence of 
a combination of 5 % limonene together with 
10% ethanol (formula 2) was applied to the third 
group. The fourth group was subjected to 
transdermal application of the chitosan film 
comprising glimepiride- β-CyD complex 
Syed et al.                                International Journal of Innovative Science and Technology                           ISSN: 2455 - 9946 
 
© 2018 IJIST Publishing Group                                              2018; 3(4), 13-25  Page 17  
equivalent to 2.5 mg glimepiride (formula 3). In 
addition, a plain chitosan film of the same size 
was applied on the animals of the fifth group. 
The blood glucose level (BGL) after oral drug 
administration and after transdermal application 
of the investigated films was measured at 
different time intervals, up to 48 h. Each animal 
served as its own control and hence, the 
hypoglycemic response was evaluated as 
percentage decrease in blood glucose level 
calculated as follows: 
% Decrease in BGL = BGL at t= 0 – BGL at t  x 100 
BGL at t= 0 
The pharmacodynamic parameters taken into 
consideration were maximum percentage 
decrease in blood glucose level, time for 
maximum response (tmax), time at which half 
peak percentage decrease in BGL prevails (t1/2 p) 
and area under percentage decrease in BGL 
versus time curve (AUC0–48 h) which was 
calculated adopting the trapezoidal rule (38). 
Statistical analysis of the results was performed 
using one-way analysis of variance (ANOVA), 
followed by the least-significant difference test 




All Animal studies were conducted according to 
the protocol approved by the Institutional 
Animal Ethics Committee, College of Pharmacy, 
Sri Satya Sai University of Technology & 
Medical University, Sehore, Madhya Pradesh, 
India. 
3. Results and Discussion 
3.1. Elucidation of the Stoichiometric Ratio 
and Preparation of Glimepiride–β–
Cyclodextrin Complex 
The absorbance values of fixed total 
concentration (0.072 mmol/l) of glimepiride and 
β-CyD were measured at 226 nm. It was found 
that the absorbance values of these solutions 
were not the same as the sum of the 
corresponding values of their components. The 
calculated absorbance difference was plotted 
against mole fraction. For a constant total 
concentration of the two species of a complex, 
the complex is in its highest concentration at the 
point where the two species are combined in the 
ratio in which they occur in the complex. Abrupt 
change in absorbance difference existed at 0.33 
drug mole fraction indicating formation of high 
order complex having stoichiometric ratio of 1 
drug: 2 cyclodextrin.  
In general, maximal absorption enhancement is 
obtained when just enough cyclodextrin is used 
to solubilize the drug. Only the free form of the 
drug, which is in equilibrium with the 
complexed one, is capable of penetrating 
lipophilic barriers and eventually entering the 
systemic circulation. Further addition of 
cyclodextrin decreases the free fraction of the 
drug and, hence, reduces the drug's 
bioavailability. Thus, glimepiride was added to 
β-CyD in this molar ratio to prepare an inclusion 
complex by the kneading method (24, 30). 
3.2. Measurement of Mechanical Properties of 
Chitosan Films 
The tensile testing provides an indication of 
the strength and elasticity of the film, which can 
be reflected by tensile strength and elongation at 
break.  
The prepared chitosan films showed a tensile 
strength at break equal to 30.88 ± 2.41 N/mm
2
 
(mean ± S.E., n = 3) and elongation % equal to 
78.32 ± 1.56. This depicts that the prepared 
chitosan films possess reasonable tensile 
properties.  
The strength property was provided from the 
use of acetic acid as a solvent for chitosan and 
the elasticity was gained by the use of lactic acid 
which is commonly used as solvent and at the 
same time as a plasticizer. 
Lactic acid could be used as a universal 
solvent for chitosan (39) and has been employed 
as a plasticizer to improve the flexibility of films 
(40). The effects of plasticization are the result 
of the plasticizer’s ability to weaken polymeric 
intermolecular attractions, thus allowing the 
polymer molecules to move more readily which 
increases the flexibility of the polymer (41).  
The elasticity of the prepared chitosan films 
would improve the contact between the film and 
the tissue, hence promoting penetration of the 
polymeric chains into the skin tissue. This leads 
to increase in the adhesion strength (42). For 
chitosan film to be applied topically, it should be 
durable, stress resistant, flexible, pliable, and 
elastic. It should be easy to apply and remove 
without incurring any upset. Moreover, the film 
must be rapidly and uniformly adherent to 
conform appropriate contact to the skin (43).  
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3.3. Characterization of Glimepiride – 
Chitosan Films 
3.3.1. Infrared Spectroscopy 
Fig. (1) depicts I.R. spectra of glimepiride 
and the investigated chitosan films. The IR 
spectra reveal that it has major peaks at 3369 cm
-
1
 due to amide stretching and at 1673 cm
-1
 
corresponding to N-H bending. The carbonyl 
group stretching peak appears at 1708 cm
-1
. In 
addition, several peaks of –C-H and =C-H 
bending in the frequency range 600 to 1500 cm
-1
 
appears in the spectrum. 
 
 
Figure 1. IR spectra of glimepiride and the investigated chitosan films 1: Glimepiride; 2: β-CyD; 3: 
glimepiride–β-CyD; 4: chitosan film comprising glimepiride– β-CyD; 5: chitosan film comprising 
glimepiride; 6: chitosan film 
The IR spectrum of the investigated β–CyD 
is characterized by an intense broad band at 
3388cm
-1
 due to O-H stretching vibrations and 
O-H bending appears at 1658 cm
-1
. The 
stretching vibrations of the =C-H and C-H 
groups appear in the 2800–3000 cm
-1 
region.  
The IR spectrum of glimepiride-β-CyD 
complex shows considerable differences when 
compared with those of their corresponding 
constituents. A decrease in frequency of a 
specific peak is generally seen on complexation 
(44), suggesting that after the formation of the 
inclusion complex, existing bonds were broken 
and also reduced in their intensities (45). 
Similarly the N–H stretching band of the amide 
exhibited broadening when the inclusion 
complex was formed. These modifications 
clearly indicate the presence of host–guest 
interactions and suggest the formation of 
hydrogen bonds between glimepiride and the 
CyD (46, 47).  
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The IR spectrum of chitosan film exhibited 
broad peak at 3434 cm
-1
 assigned to OH 
stretching, indicating intermolecular hydrogen 
bonding of chitosan molecules. The N-H 
stretching band appears at 2927 cm
-1
, also 
carbonyl stretching appears at 1733 cm
-1
. In 




In case of the chitosan films comprising 
glimepiride or glimepiride-CyD complex, the 
sharp peaks corresponding to the amide group 
stretching of glimepiride are not detectable. In 
addition, the hydroxyl and amine bending bands 
of the pure chitosan film are shifted from their 
original positions with disappearance of some 
peaks and formation of new ones. This indicates 
sort of interaction between the drug and the 
polymer. 
3.3.2. X-Ray Diffractometry 
The X-ray diffraction pattern of glimepiride 
(Fig. 2) showed sharp diffraction patterns 
reflecting its crystallinity; the highest peak was 
detectable at the 2 theta value of 24.5°.  
The diffractogram of the drug-CyD complex 
(Fig. 2) apparently differed from that of the drug 
and gave somewhat diffuse diffraction pattern 
suggesting that it is less crystalline than the drug 
per se. This was further evidenced from the data 
of the degree of crystallinity of the complex 
which was less than that of the drug. 
Crystallinity can be determined by comparing 
some representative peak heights in the 
diffraction patterns of the complex with those of 
a reference. The relationship used for the 
calculation of crystallinity was relative degree of 
crystallinity (RDC). RDC = Isam/Iref, where Isam is 
the peak height of the sample under investigation 
and Iref is the peak height at the same angle for 
the reference with the highest intensity (48). 
 
Figure 2. X-ray diffraction patterns of glimepiride and the investigated chitosan films 
1: Glimepiride; 2: glimepiride–β-CyD; 3: 
chitosan film comprising glimepiride–β- CyD; 4: 
chitosan film comprising glimepiride; 5: 
chitosan film 
The plain chitosan film showed somewhat 
diffused diffraction patterns of low intensities 
The major reflection peaks appeared at 7.3
o
 (2θ), 
9.1o (2θ) and 24.3 o (2θ). The reflection patterns 
were indicative of irregular non crystalline 
structure of the chitosan polymer. 
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For the prepared chitosan film comprising 
glimepiride or its CyD complex, their 
diffractograms contained no sharp peaks 
associated with the crystalline glimepiride 
molecule. These diffraction patterns were nearly 
similar to those of the pure chitosan film, 
suggesting that the drug was either dissolved in 
the polymer or present in an amorphous state 
within the polymeric matrix. Polymers contain 
randomly entangled chains; such an irregular 
molecular structure prevents crystallization (49).  
3.4. Release Studies of Glimepiride from 
Chitosan Films 
Release studies of the films are very crucial, 
because one needs to maintain the drug 
concentration on the surface of stratum corneum 
consistently and substantially greater than the 
drug concentration in the body, to achieve a 
constant rate of drug permeation.  
The study revealed that the % drug released 
from the chitosan film comprising glimepiride 
and that comprising glimepiride-β- CyD were 
adequate, reaching 39.68 ± 1.73 and 61.50 ± 
2.02 within 6 hours, respectively (mean ± S.E., n 
= 3). The release - rate values revealed that 
complexation of the drug within β-CyD leads to 
significant enhancement (p<0.005) of the release 




The results of the investigation suggest that 
the enhancing effect of cyclodextrin on drug 
release from the film can be explained by the 
increase in solubility of the drug by CyD 
complexation (24), thus improving the diffusible 
form of the drug species at the skin base 
interface. As the concentration gradient over the 
diffusion layer is the main driving force for the 
drug delivery from the base to the surface of the 
barrier, the availability of dissolved drug is 
crucial for effective drug delivery (50). This is 
also consistent with those reports pointing out 
that the release of drugs from vehicles was 
improved by complexation with cyclodextrins 
(14, 51-53). 
3.5. Permeation Studies 
To achieve and maintain therapeutic 
concentration of drug in blood, the resistance of 
the skin to diffusion of drugs has to be reduced 
so that drug molecules can cross skin and 
maintain therapeutic levels in blood. One long-
standing approach for improving transdermal 
drug delivery uses penetration enhancers which 
penetrate into skin to reversibly decrease the 
barrier resistance (54).  
The permeation profiles of glimepiride from 
chitosan films comprising the drug alone and in 
presence of different penetration enhancers are 
presented in Table 1 and Fig. (3). Enhancement 
of the permeation rate of the drug by 
complexation of the drug with β- CyD was 
evident. This enhancement is significant 
(p<0.001). The effect of the CyD on the 
permeation rate of drugs through the skin may 
also be attributed to the thermodynamic activity 
of the drug in the vehicle (50, 55).  It is generally 
recognized that CyDs act as true carriers by 
keeping the hydrophobic drug molecules in 
solution and delivering them to the surface of the 
biological membranes, where they partition into 
the membrane (26, 50). Though the complex 
does not penetrate the skin, the drug in the 
complex is in rapid dynamic equilibrium with 
the drug in the aqueous phase, thus continuously 
supplying the drug molecules to the skin surface 
in a diffusible form. On the other hand, CyDs act 
as penetration enhancers by increasing drug 
availability at the surface of the biological 
barrier and they are hypothesized to increase the 
drug transport through a kinetic barrier existing 
at the skin vehicle interface (50). In addition, 
drugs can be absorbed into the skin by aqueous 
pathway through hair follicles, sweat duct or 
intracellular aqueous pores in the stratum 
corneum (56-58); CyD complexation can 
increase drug flux through such aqueous pores or 
barriers (59). 





)  Enhancer 
0.037± 0.004  - (Glimepiride) 
0.067± 0.003***  -(Glimepiride–β-CyD) 
0.038± 0.005  5 % Oleic acid 
0.061 ± 0.002***  5 % Limonene 
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0.062± 0.001***  10% Limonene 
0.050± 0.002***  15 % Limonene 
0.037± 0.002  5 % Cineole 
0.031± 0.004**(Less)  5 % Menthol 
0.063± 0.001***  5 % Limonene + 10 % Ethanol 
Each value represents the mean ± S.E. (n = 3) 
** Significant difference p<0.01 
*** Significant difference p<0.001  
Incorporation of 5% oleic acid in the chitosan 
film had no significant effect on the permeation 
rate of the drug (p > 0.05) (Table 1, Fig. 3). 
Terpenes continue to be a popular choice as 
enhancers for delivering materials across skin 
membranes. It was recorded that mono- and 
sesquiterpenes are known to increase 
percutaneous resorption by increasing the 
diffusion in the stratum corneum and/or 
disruption of the intercellular lipid barrier (60, 
61).  
Incorporation of 5 % limonene (Table 1, Fig. 
3) led to significant enhancement (p<0.001) of 
the flux of the drug from the film. The increment 
of limonene concentration to 10 and 15 % also 
led to significant enhancement (p<0.001) of the 
permeation rate of the drug from the film, 
however, these further increase in concentration 
did not induce further enhancement of drug flux 
as no significant difference (p>0.05) was 
detected between the 5 % and 10 % 
concentrations of limonene. Even though, the 
enhancing effect of 15 % limonene was 
significantly less than 5 % limonene (p<0.001). 
This indicates that the permeation enhancement 
of limonene was concentration dependent and 
that the 5 % concentration was the most potent. 
Incorporation of 5% cineole showed no 
significant enhancing effect (p > 0.05). 
However, incorporation of 5 % menthol even 
declined the permeation rate of glimepiride 
through rat skin (Table 1, Fig. 3). 
It was reported that hydrocarbon terpenes 
such as limonene are generally the most 
effective terpene enhancers for lipophilic 
molecule such as steroids 54(Williams and 
Barry, 2004). Similar results were reported for 
the permeation of another lipophilic molecule, 
indomethacin, traversing rat skin (62); 
hydrocarbon terpenes, especially limonene, were 
as effective as Azone in promoting drug flux and 
oxygen containing terpenes (carvone, 1, 8-
cineole) were ineffective (63). Some structure 
activity relationships were apparent from that 
hydrocarbon terpenes were less potent enhancers 
for a model hydrophilic drug, 5-flourouracil, in 
human skin in vitro than were alcohol or ketone 
containing terpenes, and the greatest 
enhancement activity was shown by the oxide 
terpenes and terpenoids (60) However, such 
tentative structure activity relationships appear 
to be drug specific (54). 
Ethanol is commonly used in many 
transdermal formulations and is often the solvent 
of choice for use in patches; as with water; 
ethanol permeates rapidly through human skin 




A combination of 5% limonene and 10% 
ethanol was tested to evaluate their mutual 
effect. It is evident that a further significant 
enhancement (p<0.05) was achieved compared 
to the volatile oil (Table 1, Fig. 3). This may be 
due to a synergistic enhancing effect due to 
facilitated incorporation of limonene into the 
stratum corneum.  
Ethanol can exert its permeation enhancing 
activity through various mechanisms. Firstly, as 
a solvent, it can increase the solubility of the 
drug in the vehicle (65). Further, permeation of 
ethanol into the stratum corneum can alter the 
solubility properties of the tissue with a 
consequent improvement for drug partitioning 
into the membrane (66). Additionally, it is also 
feasible that the rapid permeation of ethanol or 
evaporative loss of this volatile solvent from the 
donor phase modifies the thermodynamic 
activity of the drug within the formulation. 
On the basis of the above-presented results, 
chitosan films incorporating glimepiride in 
presence of 10% ethanol together with 5% 
limonene, as well as chitosan films incorporating 
glimepiride-β- CyD complex exhibited 
distinctively marked high permeation rates.  
Accordingly, three different transdermal 
formulae for glimepiride were selected for 
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biological evaluation. These comprised: chitosan 
films containing glimepiride (formula 1), the 
same formula in presence of a combination of 5 
% limonene together with 10% ethanol (formula 
2) and chitosan film comprising glimepiride-β- 
CyD complex (formula 3). In addition, a plain 
chitosan film of the same size was also 
examined concurrently. The hypoglycemic effect 
of the selected formulations was assessed in 
diabetic rats and compared to oral administration 
of the drug. 
3.6. Assessment of Therapeutic Efficacy 
In vivo studies on diabetic rats revealed that 
BGL of the control group at different time 
intervals was higher than the corresponding level 
for the groups treated by oral or transdermal 
administration of the drug (Fig. 4). All tested 
formulae exhibited significant (p < 0.001) 
decrease in BGL compared to the plain chitosan 
film (control). The control group didn't show any 
noticeable hypoglycemic effect. Transdermal 
glimepiride formulae exhibited maximum 
hypoglycemic effect 4-6 hours post application 
and the hypoglycemic effect were sustained up 
to 48 hours. However, oral administration of the 
drug showed a peak percentage decrease in 
BGL, which was reached within 3-4 hours post 
dosing; after which a marked fast decline in 
hypoglycaemic effect was observed.  
 
 
Figure 3. Effect of penetration enhancers on the permeation of glimepiride. 
The peak of percentage decrease in BGL (Table 
2) for the orally administered drug was higher 
than that for formulae 1; the difference is 
significant (P<0.01). However, there is no 
significant difference (P<0.05) between the oral 
drug and formulae 2 and 3. This points out that 
the use of a combination of penetration 
enhancers, limonene and ethanol, or the use of 
glimepiride-β-CyD led to a significant increase 
in peak hypoglycaemic effect to such an extent 
reaching values comparable to that of the oral 
administration (Table 2). 
The values of tmax for the transdermal 
formulae 1 and 2 were higher than that after oral 
administration of the drug the difference is 
significant (P<0.01). On the other hand, there is 
no significant difference (P<0.05) between the 
oral drug and formula 3 which contains 
glimepiride-β-CyD complex (Table 2).  
The values of half peak time (t1/2p) for the 
investigated transdermal formulae presented in 
Table 2 were much higher than the 
corresponding values after oral administration, 
indicating prolongation of drug action; the 
difference is significant (P<0.001). Regarding 
the area under the curve of percentage decrease 
in BGL versus time, the values of AUC0–48h 
for the transdermal formulae were higher than 
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that of the orally administered drug; this 
difference is very highly significant, indicating 
that glimepiride-chitosan films afford adequate 
bioavailability of the drug (Table 2). 
 
 
Figure 4. Percentage decrease in BGL after oral administration and transdermal application of 
glimepiride. 
 
Table 2 Effect of Transdermal Formulations of Glimepiride on its Pharmacodynamic Parameters in 
Diabetic Rats 
Treatment Pharmacodynamic Parameter 






Oral glimepiride 33.01±1.52  3.33±0.70  8.16±1.03  399.42±29.06 
Formula 1  25.70±1.45**
(Less)
  6.00±0.00**  36.05±1.26***  860.42±47.42*** 
Formula 2  30.66±1.34  5.33±0.67**  36.83±1.31***  966.25±29.39*** 
Formula 3  35.20±1.73  4.00±0.20  37.12±1.258***  1228.64±86.09*** 
1
 t1/2p: the time span during which the % 
decrease in blood glucose level of the drug is 
equal or higher than half its peak 
** Significant difference p<0.01 
*** Significant difference p<0.001 
The above results demonstrate that chitosan 
films may offer an attractive, non-irritant, safe 
and economic transdermal delivery system for 
glimepiride. The prepared films are 
characterized by an intensity of action 
comparable to that of the orally administered 
drug accompanied with an increase in duration 
of action extending up to 48 h. 
4. Conclusions 
In conclusion, transdermal delivery of 
glimepiride affords solution to many problems 
associated with oral administration problems. 
The annoyance of dizziness and gastric 
disturbances is avoided; consequently, patient 
compliance is increased. Transdermal delivery 
provides steadier basal blood drug levels due to 
prolonged delivery of the drug; thus, it prevents 
sub-therapeutic troughs and also reduces 
individual, variations. It avoids dangerous peaks 
which are the main cause of severe 
hypoglycaemia within the initial hours, in 
addition to the feasibility of termination of 
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treatment when necessary. Transdermal 
glimepiride will help to maintain good 
glycaemic control for relatively prolonged 
period of time and, in turn, might help to 
prevent long term complications. 
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